Important legal notice
Contact   |   Search on Europa   

Infectious Diseases Graphic element print icon Graphic element
  Homepage
Graphic element General information
  RTD Infectious Diseases Unit
  Developing countries
  EDCTP
   
Graphic element Projects
  About FP6 Funding
  FP6 projects
  About FP5 Funding
  FP5 projects
   
   
Graphic element Addressed Diseases
  HIV/AIDS
- News
  Malaria
  Tuberculosis
   
Graphic element Calls for proposals
  FP7 Calls
   
Graphic element Contact corner
  Unit
  Scientific officers
  Subscribe to our mailing list
   
 
Tuberculosis China
TUBERCULOSIS
Framework programme: 6
Call: 2
Project number:
LSHP-CT-2005-012166
EC contribution: € 150,000
Duration: 24 months
Type: SSA
Starting date: 1 June 2005
Graphic element The Diversity of Mycobacterium Tuberculosis Strains in China: Tracing the Origins of the Worldwide Dispersion of the Multidrug-Resistant Beijing Genotype
Keywords: China; Mycobacterium tuberculosis; diversity; molecular epidemiology; VNTR typing; Beijing genotype; multidrug-resistance

Summary:

This project proposes to organise the analysis of a large collection of strains (3 000) from the 31 provinces of China and the data will be compared to the characteristics of strains collected in other countries. This will produce knowledge on the diversity of Chinese TB strains and show whether the dispersion of the Beijing type is of clonal origin.

Background:

The Beijing genotype is prevalent in China. Strains of a similar genotype are found worldwide, particularly in Eastern Europe and in the countries of the former Soviet Union, and are often associated with multidrug-resistance. The very rapid and efficient dispersion of the Beijing strains suggest that they may have developed selective advantages.

Aim:

The present SSA aims at preparing the project in collaboration with Chinese scientists, transfer the technical knowledge, follow the progress of the experiments, collect the data in a shared-database and produce population analyses.

Expected results:

The different partners will first define the characteristics of the population to be included in the protocol, and choose the appropriate methods for genotyping and multidrug-resistance (MDR) assessment. Data on the BCG status, age and gender of the patients as well as other relevant clinical information will be collected. Technical knowledge will be transmitted when necessary to Chinese laboratories through exchanges.

Potential applications:

In China, a large proportion of the population is infected by Mycobacterium tuberculosis with 500 000 new cases every year. The attenuated Mycobacterium bovis Bacillus Calmette Guerin (BCG) is the only available vaccine against TB. However, this vaccine does not provide consistent protection against TB. Knowledge of the diversity of the M tuberculosis strains is of major importance to identify M. tuberculosis antigens and epitopes for new protective vaccines and specific diagnostic reagents.

Coordinator:

Christine Pourcel
GPMS
Institut de Génétique et Microbiologie, Bât 400
Université Paris Sud-XI
91405 Orsay Cedex
France
Tel: +33 1 69 15 30 01
Fax: +33 1 69 15 66 78
E-mail: christine.pourcel@igmors.u-psud.fr
Website: http://www.u-psud.fr/

Partners:

Principal
Scientific
Participants
Official Address Other Information
2Dick van Soolingen

National Mycobacteria
Reference Laboratory
National Institute of Public Health and the Environment
PO BOX 1
NL-3720 BA Bilthoven
The Netherlands

Tel: +31 30 2742363
Fax: +31 30 2744418
E-mail: D.van.Soolingen@rivm.nl
Websites:
http://www.rivm.nl
http://www.caontb.rivm.nl

 
 
top
Graphic element